Literature DB >> 7842147

Applicability of clinical pharmacotherapy guidelines for major depression in primary care settings.

H C Schulberg1, M R Block, M J Madonia, E Rodriguez, C P Scott, J Lave.   

Abstract

OBJECTIVE: To determine whether guidelines established for pharmacologic treatment of major depression are feasible in primary care.
DESIGN: Prospective cohort study.
SETTING: Ambulatory family health centers and internal medicine clinics. PATIENTS: Ninety-one primary care patients meeting criteria within the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition for a current major depression randomized to receive antidepressant medication after being judged by a psychiatrist as clinically eligible for pharmacotherapy in an ambulatory setting. INTERVENTION: Nortriptyline hydrochloride prescribed by primary care physicians trained in clinical guidelines specifying dosage schedules, durations, and procedures resembling those recommended by the AHCPR (Agency for Health Care Policy and Research) Depression Guideline Panel. MAIN OUTCOME MEASURES: Patient participation and continuation in medication treatment.
RESULTS: Fifty-five percent of patients completed the acute phase of treatment after a mean of 6.9 visits extending over a mean of 8.1 weeks. Of those patients entering the continuation phase, 60% completed the follow-up visits for 6 months. Taken together, only 33% of patients assigned to receive antidepressant medication completed the full regimen recommended by the AHCPR guidelines.
CONCLUSIONS: The treatment of depressed primary care patients within AHCPR guidelines for antidepressant medication is feasible but complex. Although primary care physicians ably adhere to these guidelines, keeping patients in treatment is difficult and possibly requires greater flexibility in treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7842147     DOI: 10.1001/archfami.4.2.106

Source DB:  PubMed          Journal:  Arch Fam Med        ISSN: 1063-3987


  8 in total

Review 1.  Which clinical practice guidelines for depression? An overview for busy practitioners.

Authors:  P L Cornwall; J Scott
Journal:  Br J Gen Pract       Date:  2000-11       Impact factor: 5.386

2.  Do practice guidelines augment drug utilisation review?

Authors:  E A Chrischilles; K Gondek
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 3.  Awareness, diagnosis, and treatment of depression.

Authors:  L S Goldman; N H Nielsen; H C Champion
Journal:  J Gen Intern Med       Date:  1999-09       Impact factor: 5.128

4.  Symptoms of major depression and tricyclic side effects in primary care patients.

Authors:  B L Rollman; M R Block; H C Schulberg
Journal:  J Gen Intern Med       Date:  1997-05       Impact factor: 5.128

5.  Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation.

Authors:  Emmy Rood; Robert Jan Bosman; Johan Ids van der Spoel; Paul Taylor; Durk Freark Zandstra
Journal:  J Am Med Inform Assoc       Date:  2004-11-23       Impact factor: 4.497

6.  Stepped care treatment for depression and anxiety in primary care. a randomized controlled trial.

Authors:  Wike Seekles; Annemieke van Straten; Aartjan Beekman; Harm van Marwijk; Pim Cuijpers
Journal:  Trials       Date:  2011-07-07       Impact factor: 2.279

7.  Stepped care for depression and anxiety: from primary care to specialized mental health care: a randomised controlled trial testing the effectiveness of a stepped care program among primary care patients with mood or anxiety disorders.

Authors:  Wike Seekles; Annemieke van Straten; Aartjan Beekman; Harm van Marwijk; Pim Cuijpers
Journal:  BMC Health Serv Res       Date:  2009-06-05       Impact factor: 2.655

8.  Controlled trial of the impact of a BC adult mental health practice support program (AMHPSP) on primary health care professionals' management of depression.

Authors:  Bianca Lauria-Horner; Tara Beaulieu; Stephanie Knaak; Rivian Weinerman; Helen Campbell; Scott Patten
Journal:  BMC Fam Pract       Date:  2018-11-28       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.